Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Deloitte
US Army
Accenture
Baxter
Cipla
Fish and Richardson
Chinese Patent Office
US Department of Justice

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201922

« Back to Dashboard

NDA 201922 describes XIMINO, which is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the XIMINO profile page.

The generic ingredient in XIMINO is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
Summary for 201922
Tradename:XIMINO
Applicant:Sun Pharm Inds Ltd
Ingredient:minocycline hydrochloride
Patents:7
Therapeutic Class:Antibacterials
Dental and Oral Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 201922
Ingredient-typeTetracyclines
Medical Subject Heading (MeSH) Categories for 201922
Suppliers and Packaging for NDA: 201922
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Ranbaxy Laboratories Inc. 10631-330 N 10631-330-30
XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Ranbaxy Laboratories Inc. 10631-330 N 10631-330-06

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 45MG BASE
Approval Date:Jul 11, 2012TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Feb 19, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Patent:➤ Sign UpPatent Expiration:Apr 2, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Patent:➤ Sign UpPatent Expiration:Apr 2, 2027Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 201922

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
US Department of Justice
Daiichi Sankyo
Johnson and Johnson
Colorcon
Dow
QuintilesIMS
Fuji
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.